Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab with PD-1 blockade in metastatic melanoma with bone involvement
DRKS00016064Phase 4Completed
- Sponsor
- Alcedis
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of denosumab, nivolumab, pembrolizumab and ipilimumab in cutaneous melanoma (CM), Primary bone malignancy (None.) and Bone marrow metastasis (BMM), sponsored by Alcedis. Primary endpoint: Immunological effects of denosumab with PD-1 blockade. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
cutaneous melanoma (CM)Primary bone malignancy (None.)Bone marrow metastasis (BMM)
Beyond the preview
Go deeper on DRKS00016064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00016064.